GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » PS Ratio

GYRE (Gyre Therapeutics) PS Ratio : 8.83 (As of Mar. 27, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Gyre Therapeutics's share price is $9.09. Gyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $1.03. Hence, Gyre Therapeutics's PS Ratio for today is 8.83.

The historical rank and industry rank for Gyre Therapeutics's PS Ratio or its related term are showing as below:

GYRE' s PS Ratio Range Over the Past 10 Years
Min: 5.73   Med: 10.95   Max: 26.34
Current: 8.83

During the past 4 years, Gyre Therapeutics's highest PS Ratio was 26.34. The lowest was 5.73. And the median was 10.95.

GYRE's PS Ratio is ranked better than
50% of 986 companies
in the Biotechnology industry
Industry Median: 8.555 vs GYRE: 8.83

Gyre Therapeutics's Revenue per Sharefor the three months ended in Dec. 2024 was $0.27. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $1.03.

Warning Sign:

Gyre Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Gyre Therapeutics was -40.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -4.00% per year.

During the past 4 years, Gyre Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -4.00% per year. The lowest was -4.00% per year. And the median was -4.00% per year.

Back to Basics: PS Ratio


Gyre Therapeutics PS Ratio Historical Data

The historical data trend for Gyre Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics PS Ratio Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
PS Ratio
- - 14.91 11.70

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 14.91 12.31 9.33 11.31 11.70

Competitive Comparison of Gyre Therapeutics's PS Ratio

For the Biotechnology subindustry, Gyre Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gyre Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's PS Ratio falls into.


;
;

Gyre Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Gyre Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.09/1.029
=8.83

Gyre Therapeutics's Share Price of today is $9.09.
Gyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Gyre Therapeutics  (NAS:GYRE) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Gyre Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gyre Therapeutics Business Description

Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.